Together, these findings support the claim that the deregulation of LIMD1 expression in different cancers mainly results from epigenetic reprogramming rather than its mutation, with its downregulation in NSCLC being partially attributed to promoter methylation and arm-level deletion. This evidence concerns the gene LIMD1 and non-small cell lung carcinoma.